Compare JetBlue Airways Corporation (JBLU) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs GeneDx Holdings Corp — how do they compare? JetBlue Airways Corporation trades at $3.84 (market cap $1.48B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: GeneDx Holdings Corp is the larger of the two by market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JetBlue Airways Corporation for 44 Days and GeneDx Holdings Corp for 19 Days on average.
| JBLU | WGS | |
|---|---|---|
Market Cap | $1.48B | $2.02B |
Volume | 30,275,693 | 734,640 |
Sector | Industrials | Health |
52-Week High | $6.46 | $167.51 |
52-Week Low | $3.84 | $34.51 |
Typical Hold Time | 44 Days | 19 Days |
Enterprise Value | $8.84B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $3.92, down 1.26% today, reflecting ongoing operational challenges. The airline faces persistent profitability issues with a net income margin of -9.32% and negative ROE of -44.36%. Recent Q2 2026 earnings beat expectations but followed two consecutive misses. Technical indicators show bearish momentum with the stock trading near key support levels. The company continues expansion efforts with new Colombia routes while grappling with high fuel costs and capacity constraints.
Investment outlook remains cautious given sustained losses and high debt levels. The consensus price target of $5.89 offers 50% upside potential, but execution risks from fuel price volatility and competitive pressures persist. Analyst sentiment leans neutral with 62% hold ratings, suggesting limited near-term catalysts for significant price appreciation despite attractive valuation multiples.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
